Clinical Trials
45
Active:6
Completed:18
Trial Phases
4 Phases
Phase 1:20
Phase 2:11
Phase 3:8
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (45 trials with phase data)• Click on a phase to view related trials
Phase 1
20 (44.4%)Phase 2
11 (24.4%)Phase 3
8 (17.8%)Not Applicable
6 (13.3%)A Single Ascending Dose of HRS-2162 in Healthy Subjects
Not Applicable
Not yet recruiting
- Conditions
- Reversal of Neuromuscular Blockade
- Interventions
- Drug: HRS-2162Drug: Placebo
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT07195604
- Locations
- 🇨🇳
Sichuan Academy of Medical Sciences &Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Not Applicable
Recruiting
- Conditions
- Lipoprotein Disorder
- Interventions
- Drug: HRS-5632 InjectionDrug: HRS-5632 Injection Placebo
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT07185776
- Locations
- 🇨🇳
The Second Affiliated Hospital of AFMU, Xi’an, Shanxi, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi, China
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects
Not Applicable
Not yet recruiting
- Conditions
- Overweight or Obesity
- Interventions
- Drug: HRS-9531 Tablet
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT07150962
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.
Not Applicable
Recruiting
- Conditions
- Subjects With Mild Hypertension
- Interventions
- Drug: HRS-9563, placebo
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT07117474
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
Not Applicable
Recruiting
- Conditions
- Hyperlipidemia
- Interventions
- Drug: HRS-7249 Injection
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT07100418
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai Municipality, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found